A team of Chinese researchers has developed a handheld cancer detection device capable of identifying early-stage cancer biomarkers from just a single drop of blood, a breakthrough that could potentially
make cancer screening faster, cheaper, and far more accessible in the future.
Developed by scientists at Westlake University in China, the portable device reportedly achieved up to 94.9% accuracy in detecting early-stage lung cancer biomarkers during clinical testing. Researchers say the technology could eventually help move advanced cancer diagnostics beyond specialised laboratories and into clinics, remote healthcare settings, and even home-based monitoring.
How The Device Works
Traditional cancer biomarker detection often relies on large laboratory systems equipped with complex optical instruments, spectrometers, and specialised testing equipment. These systems are not only expensive but also largely limited to advanced medical centres.
The newly developed handheld device dramatically reduces that complexity.
According to the research published in Nature Photonics, the system uses a light-based sensing technique called Q-modulated refractometric sensing to identify tiny biological particles known as small extracellular vesicles (sEVs), which can serve as early indicators of lung cancer.
The compact system reportedly contains only three major components:
A 3D sensing chip
An LED light source
A photodetector
Researchers also used specially engineered metamaterials and nanophotonic technology to improve detection sensitivity while significantly reducing the device’s size.
What The Trial Results Showed
During testing involving more than 170 serum samples from lung cancer patients, the device achieved:
Up to 94.9% accuracy for early lung cancer detection
Around 92.1% accuracy for post-surgical monitoring
Nearly 10,000 times greater sensitivity compared to conventional ELISA testing methods
Researchers also reported that the device could identify cancer biomarkers in approximately 15 minutes, potentially much faster than many traditional laboratory procedures.
Why Experts Are Paying Attention
The development comes at a time when scientists worldwide are increasingly exploring “liquid biopsy” technologies, non-invasive blood-based tests capable of identifying cancer-related markers without surgery or tissue removal.
Portable diagnostic systems could be especially significant for rural regions and healthcare systems with limited access to specialised cancer screening infrastructure. However, experts also caution that the technology is still in the early stages of development. Larger clinical trials, peer-reviewed validation, regulatory approvals, and long-term performance assessments will still be required before the device can be used routinely in hospitals or home settings.
Some researchers online have additionally pointed out that accuracy figures alone do not fully determine the effectiveness of cancer screening tools, and metrics such as sensitivity, specificity, and false-negative rates remain equally important in evaluating real-world clinical performance.
Still, the breakthrough highlights how rapidly cancer diagnostics are evolving and how future screening may become smaller, faster, and significantly more accessible than ever before.
